三井住友金融集团CEO：个人认为，不预期英伟达的管理层立场会发生显著变化。

Phrontline Biopharma, a China-based antibody‑drug conjugate (ADC) developer, said it closed a Series A round of nearly $40m, bringing total new investment to about $100m over the past year. The round was led by Yuanhe Origin and Decheng Capital, with participation from Longpan Investment, Jifeng Capital, Mifang Health Fund, Songqing Capital and Jianfa Emerging Investment; Dianshi Capital served as exclusive financial adviser. Proceeds will accelerate clinical development of the core pipeline, support IND filings for differentiated reserve candidates, build a new payload platform and expand international collaborations and capitalization efforts.

A-share 'Zhong' concept stocks saw pockets of afternoon strength. Zhongcheng Co. jumped to its daily limit; China Railway Assembly, Zhongshi Media, China Textile Standards, China Haicheng and COFCO Tech & Industry also rallied.